Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Medicine and Dentistry

• Janus Kinase Inhibitor 100%
• Therapeutic Procedure 80%
• Cancer 60%
• Patient 60%
• Diseases 40%
• Hematologic Malignancy 40%
• Janus Kinase 40%
• Ruxolitinib 40%
• Malignant Neoplasm 40%
• Neoplasm 20%
• Infection 20%
• Immune Response 20%
• Immunosuppressive Drug 20%
• Loss of Function Mutation 20%
• Combination Therapy 20%
• Autoimmune Disease 20%
• Cytokine 20%
• Lymphocyte 20%
• Immune Deficiency 20%
• Gain of Function Mutation 20%
• Immunosuppressive Treatment 20%
• Health 20%
• Immunocompetent Cell 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Janus Kinase Inhibitor 100%
• Myeloproliferative Neoplasm 60%
• Diseases 40%
• Hematologic Malignancy 40%
• Malignant Neoplasm 40%
• Janus Kinase 40%
• Ruxolitinib 40%
• Clinical Trial 40%
• Neoplasm 20%
• Cytokine 20%
• Immunosuppressive Agent 20%
• Infection 20%
• Autoimmune Disease 20%

Immunology and Microbiology

• Immunity 40%
• Immune Response 20%
• Autoimmune Disease 20%
• Mutation 20%
• Gain of Function Mutation 20%
• Loss of Function Mutation 20%
• Immunosuppressive Drug 20%
• Lymphocyte 20%
• Electric Potential 20%
• Health 20%
• Immunocompetent Cell 20%